184 related articles for article (PubMed ID: 38539479)
21. Homeostasis of the gut barrier and potential biomarkers.
Wells JM; Brummer RJ; Derrien M; MacDonald TT; Troost F; Cani PD; Theodorou V; Dekker J; Méheust A; de Vos WM; Mercenier A; Nauta A; Garcia-Rodenas CL
Am J Physiol Gastrointest Liver Physiol; 2017 Mar; 312(3):G171-G193. PubMed ID: 27908847
[TBL] [Abstract][Full Text] [Related]
22. Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy.
Tian M; Zhang S; Tseng Y; Shen X; Dong L; Xue R
Anticancer Agents Med Chem; 2022; 22(7):1244-1256. PubMed ID: 34229597
[TBL] [Abstract][Full Text] [Related]
23. Rhubarb Enema Increasing Short-Chain Fatty Acids that Improves the Intestinal Barrier Disruption in CKD May Be Related to the Regulation of Gut Dysbiosis.
Ji C; Lu F; Wu Y; Lu Z; Mo Y; Han L; Lin Q; Liu X; Zou C
Biomed Res Int; 2022; 2022():1896781. PubMed ID: 35097110
[TBL] [Abstract][Full Text] [Related]
24. Putative intestinal permeability markers do not correlate with cardiometabolic health and gut microbiota in humans, except for peptides recognized by a widely used zonulin ELISA kit.
Arango-González A; Lara-Guzmán OJ; Rivera DA; Álvarez R; Salazar-Serrano D; Muñoz-Durango K; Escobar JS; Sierra JA
Nutr Metab Cardiovasc Dis; 2023 Jan; 33(1):112-123. PubMed ID: 36462977
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.
Zhang F; Ferrero M; Dong N; D'Auria G; Reyes-Prieto M; Herreros-Pomares A; Calabuig-Fariñas S; Duréndez E; Aparisi F; Blasco A; García C; Camps C; Jantus-Lewintre E; Sirera R
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34063829
[TBL] [Abstract][Full Text] [Related]
26. Elevated Levels of Circulating Biomarkers Related to Leaky Gut Syndrome and Bacterial Translocation Are Associated With Graves' Disease.
Zheng D; Liao H; Chen S; Liu X; Mao C; Zhang C; Meng M; Wang Z; Wang Y; Jiang Q; Xue Y; Zhou L; Chen Y
Front Endocrinol (Lausanne); 2021; 12():796212. PubMed ID: 34975767
[TBL] [Abstract][Full Text] [Related]
27. Midgut microbiota affects the intestinal barrier by producing short-chain fatty acids in
Song M; Zhang Z; Li Y; Xiang Y; Li C
Front Microbiol; 2023; 14():1263731. PubMed ID: 37915855
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers for monitoring the equine large intestinal inflammatory response to stress-induced dysbiosis and probiotic supplementation.
Collinet A; Grimm P; Jacotot E; Julliand V
J Anim Sci; 2022 Oct; 100(10):. PubMed ID: 35980768
[TBL] [Abstract][Full Text] [Related]
29. Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor.
Yu J; Xiong F; Xu Y; Xu H; Zhang X; Gao H; Li Y
Int Immunopharmacol; 2024 Jan; 127():111412. PubMed ID: 38160567
[TBL] [Abstract][Full Text] [Related]
30.
Hamada K; Isobe J; Hattori K; Hosonuma M; Baba Y; Murayama M; Narikawa Y; Toyoda H; Funayama E; Tajima K; Shida M; Hirasawa Y; Tsurui T; Ariizumi H; Ishiguro T; Suzuki R; Ohkuma R; Kubota Y; Sambe T; Tsuji M; Wada S; Kiuchi Y; Kobayashi S; Kuramasu A; Horiike A; Kim YG; Tsunoda T; Yoshimura K
Front Immunol; 2023; 14():1164724. PubMed ID: 37207204
[TBL] [Abstract][Full Text] [Related]
31. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
32. A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier.
Liu W; Luo X; Tang J; Mo Q; Zhong H; Zhang H; Feng F
Eur J Nutr; 2021 Aug; 60(5):2317-2330. PubMed ID: 33180143
[TBL] [Abstract][Full Text] [Related]
33. Transplantation of fecal microbiota rich in short chain fatty acids and butyric acid treat cerebral ischemic stroke by regulating gut microbiota.
Chen R; Xu Y; Wu P; Zhou H; Lasanajak Y; Fang Y; Tang L; Ye L; Li X; Cai Z; Zhao J
Pharmacol Res; 2019 Oct; 148():104403. PubMed ID: 31425750
[TBL] [Abstract][Full Text] [Related]
34. The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer.
Naqash AR; Kihn-Alarcón AJ; Stavraka C; Kerrigan K; Maleki Vareki S; Pinato DJ; Puri S
Ann Transl Med; 2021 Jun; 9(12):1034. PubMed ID: 34277834
[TBL] [Abstract][Full Text] [Related]
35. Reduced fecal short-chain fatty acids levels and the relationship with gut microbiota in IgA nephropathy.
Chai L; Luo Q; Cai K; Wang K; Xu B
BMC Nephrol; 2021 Jun; 22(1):209. PubMed ID: 34082732
[TBL] [Abstract][Full Text] [Related]
36. Partially hydrolyzed guar gum attenuates non-alcoholic fatty liver disease in mice through the gut-liver axis.
Takayama S; Katada K; Takagi T; Iida T; Ueda T; Mizushima K; Higashimura Y; Morita M; Okayama T; Kamada K; Uchiyama K; Handa O; Ishikawa T; Yasukawa Z; Okubo T; Itoh Y; Naito Y
World J Gastroenterol; 2021 May; 27(18):2160-2176. PubMed ID: 34025071
[TBL] [Abstract][Full Text] [Related]
37. Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities.
Al-Qadami GH; Secombe KR; Subramaniam CB; Wardill HR; Bowen JM
Microorganisms; 2022 Oct; 10(10):. PubMed ID: 36296324
[TBL] [Abstract][Full Text] [Related]
38. Gut Microbiota and Immune System Interactions.
Yoo JY; Groer M; Dutra SVO; Sarkar A; McSkimming DI
Microorganisms; 2020 Oct; 8(10):. PubMed ID: 33076307
[TBL] [Abstract][Full Text] [Related]
39. Fecal microbiota transplantation and replenishment of short-chain fatty acids protect against chronic cerebral hypoperfusion-induced colonic dysfunction by regulating gut microbiota, differentiation of Th17 cells, and mitochondrial energy metabolism.
Su SH; Wu YF; Lin Q; Zhang L; Wang DP; Hai J
J Neuroinflammation; 2022 Dec; 19(1):313. PubMed ID: 36567333
[TBL] [Abstract][Full Text] [Related]
40. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
